المؤلفون: Nelson, Brad H, Hamilton, Phineas T, Phung, Minh Tung, Milne, Katy, Harris, Bronwyn, Thornton, Shelby, Stevens, Donald LI, Kalaria, Shreena, Singh, Karanvir, Laumont, Céline M, Moss, Elena, Alimujiang, Aliya, Meagher, Nicola S, Bolithon, Adelyn, Fereday, Sian, Kennedy, Catherine J, Hendley, Joy, Ariyaratne, Dinuka, Alsop, Kathryn, Traficante, Nadia, Goode, Ellen L, Karnezis, Anthony N, Shen, Hui, Richardson, Jean, Deurloo, Cindy McKinnon, Chase, Anne, Grout, Bronwyn, Doherty, Jennifer A, Harris, Holly R, Cushing-Haugen, Kara L, Anglesio, Michael S, Heinze, Karolin, Huntsman, David, Talhouk, Aline, Hanley, Gillian E, Alsop, Jennifer, Jimenez-Linan, Mercedes, Pharoah, Paul DP, Boros, Jessica, Brand, Alison H, Harnett, Paul R, Sharma, Raghwa, Hecht, Jonathan L, Sasamoto, Naoko, Terry, Kathryn L, Karlan, Beth Y, Lester, Jenny, Carney, Michael E, Goodman, Marc T, Hernandez, Brenda Y, Wilkens, Lynne R, Behrens, Sabine, Fortner, Renée Turzanski, Fasching, Peter A, Bisinotto, Christiani, dos Reis, Francisco José Candido, Ghatage, Prafull, Köbel, Martin, Elishaev, Esther, Modugno, Francesmary, Cook, Linda S, Le, Nhu D, Gentry-Maharaj, Aleksandra, Menon, Usha, García, María J, Rodriguez-Antona, Cristina, Farrington, Kyo M, Kelemen, Linda E, Kommoss, Stefan, Staebler, Annette, Garsed, Dale W, Brenton, James D, Piskorz, Anna M, Bowtell, David DL, DeFazio, Anna, Ramus, Susan J, Pike, Malcolm C, Pearce, Celeste Leigh

المصدر: Journal of Clinical Investigation. 134(24)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Women's Health, Ovarian Cancer, Rare Diseases, Orphan Drug, Humans, Female, Tumor Microenvironment, Ovarian Neoplasms, Cancer Survivors, Middle Aged, Aged, CD8-Positive T-Lymphocytes, Neoplasm Proteins, Adult, Cellular immune response, Epidemiology, Oncology, Medical and Health Sciences, Biological sciences, Biomedical and clinical sciences, Health sciences

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/1bw0j4gj
https://escholarship.org/content/qt1bw0j4gj/qt1bw0j4gj.pdf

المؤلفون: Xiang, Yi, Zhao, Zhongchao, Yao, Emmie, Balayan, Alis, Fiering, Steven, Steinmetz, Nicole, Chen, Shaochen

مصطلحات موضوعية: 3D bioprinting, Cancer immunotherapy, Cowpea mosaic virus, In vitro models, Ovarian cancer, Female, Ovarian Neoplasms, Comovirus, Spheroids, Cellular, Bioprinting, Animals, Humans, Mice, Cell Line, Tumor, Immunotherapy, Macrophages

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/6573v3hh
https://escholarship.org/content/qt6573v3hh/qt6573v3hh.pdf

المؤلفون: Zhang, Yichi, Ojalill, Marjaana, Boyer, Antonia, Chen, Xiao Lei, Tahon, Elise, Thivolle Lioux, Gaëtan, Xia, Marvin, Abbas, Maryam, Soylu, Halime Meryem, Flieder, Douglas B, Connolly, Denise C, Molinolo, Alfredo A, McHale, Michael T, Stupack, Dwayne G, Schlaepfer, David D

المصدر: Cancer Research Communications. 4(12)

مصطلحات موضوعية: Biochemistry and Cell Biology, Biological Sciences, Cancer, Ovarian Cancer, Women's Health, Rare Diseases, 4.2 Evaluation of markers and technologies, Humans, Female, Cisplatin, Ovarian Neoplasms, Cell Line, Tumor, Focal Adhesion Kinase 1, Antineoplastic Agents, Cell Nucleus, Cell Survival, MAP Kinase Signaling System, Focal Adhesion Protein-Tyrosine Kinases

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/1z95c9nn
https://escholarship.org/content/qt1z95c9nn/qt1z95c9nn.pdf

المصدر: A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Cancer Moonshot Biobank Research Protocol

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

المؤلفون: NRG Oncology

المصدر: Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

المصدر: FAST HOC-FAPI PET for Staging of High-Grade Serous Ovarian Cancer .

المؤلفون: GOG Foundation

المصدر: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Mori KM, Giuliano PD, Lopez KL, King MM, Bohart R, Goldstein BH. Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient. Anticancer Drugs. 2019 Nov;30(10):1064-1066. doi: 10.1097/CAD.0000000000000836.
Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, Holloway RW. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021 Dec;163(3):481-489. doi: 10.1016/j.ygyno.2021.10.069. Epub 2021 Oct 20. Erratum In: Gynecol Oncol. 2022 May;165(2):401. doi: 10.1016/j.ygyno.2022.02.014.
Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, Fitzsimmons CK, Kennard JA, King M, LeBlanc J, Lopez K, Manyam M, McKenzie ND, Mori KM, Stephens AJ, Sarfraz A. 2020 International Gynecologic Cancer Society, Oral Plenary Session presentation of VIRO-15 Phase 2 Trial Data, Robert Holloway, AdventHealth Cancer Institute, Orlando, FL. International Journal of Gynecologic Cancer 2020;30:A9-A10
Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007.

المصدر: Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR)

المساهمون: Myong Cheol Lim, Principal investigator

المصدر: Randomized Phase III Trial of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Resistant Recurrent Ovarian Cancer: KOV-02R - Resistant Cancer of Ovary (RECOVER)

المساهمون: Myong Cheol Lim, MD, PhD, Principal Researcher

المصدر: Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Primary Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS, KOV-04)

المؤلفون: Merck Sharp & Dohme LLC

المساهمون: Rebecca Arend, Professor of Medicine, Division Director Gynecology Oncology

المصدر: A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carbo/Taxol/Pembro in Patients Receiving Neoadjuvant Chemotherapy (NACT) Followed by Olaparib/Pembro Maintenance

المصدر: Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy

المصدر: Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host

المصدر: Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies

المساهمون: OSMAN KÖSE, MD, assistant professor

المصدر: The Impact of the Inflammation Index on Predicting Postoperative Complications in Ovarian Cancer

المؤلفون: North-Eastern German Society of Gynecological Oncology e.V. (NOGGO e.V.)

المصدر: Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing

Other URLs: https://astrazenecagroup-dt.pharmacm.com/DT/Home

المصدر: A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors